The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|November 27, 2021
Endocrine Month in Review: November 2021
Advertisement
Editor's note: Clicking in the center of a slide will redirect you to that article or video.
Top Stories of November
International Osteoporosis Foundation Issues Review of Links Between Bone Loss and Vascular Calcification
The latest review from the International Osteoporosis Foundation is a 14-page document with more than 100 references outlining current data related to the pathophysiological links between vascular calcification and bone loss.Dapagliflozin Slows Rate of Kidney Function Decline, Regardless of Diabetes Status
Data from a prespecified analysis of DAPA-CKD presented at Kidney Week 2021 provides insight into the effects of dapagliflozin use on the rate of kidney function decline based on the presence of type 2 diabetes from the trial.Diabetes Community Celebrates Build Back Better Act, Potential for $35 Insulin Caps
Diana Isaacs, PharmD, discusses the Build Back Better Act, the potential impact of a monthly spending cap on insulin, and reflects on the progress that has been made in regard to insulin affordability during the 100-year anniversary of the discovery of insulin.CLICK Trial: Chlorthalidone Reduces BP in Chronic Kidney Disease and Uncontrolled Hypertension
Data from the CLICK trial presented at Kidney Week 2021 demonstrates chlorthalidone reduced systolic blood pressure by 11 mmHg over a 12-week treatment period among a patient population with stage 4 CKD and uncontrolled hypertension.Patients with Diabetes Less Likely to Recognize, Report AFib Symptoms
Data from the SWISS-AF study is providing clinicians with insight into the likelihood of patients to perceive symptoms of atrial fibrillation based on whether or not they had diabetes.Finerenone Could Reduce Progression to Dialysis in Type 2 Diabetes and CKD
An analysis of secondary end points from FIGARO-DKD presented at Kidney Week 2021 provides further insight into the effects of finerenone on kidney outcomes, including a 36% reduction in need for dialysis.
Advertisement
Related to this article
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.
Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
The designation follows phase 2 IMPACT trial data showing reduced adverse pregnancy outcomes in high-risk antiphospholipid syndrome.
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
Advertisement
Advertisement